Skip to main content

Market Overview

FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation


The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia.

  • The designation intends to expedite the development and review of certain product candidates.
  • After a routine review of TRANQUILITY study data, a lower 30 mcg dose showed numerical improvements compared to the placebo.
  • Earlier this year, the company announced positive topline data from the Phase 1b/2 TRANQUILITY study.
  • Price Action: BTAI shares gained 8.53% at $51 in premarket on the last check Monday.

Related Articles (BTAI)

View Comments and Join the Discussion!

Posted-In: dementiaBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at